Obesity Therapies: Present and Future Opportunities
Wednesday, June 05, 2024
Breakout Session
Business Development and Finance
30ABC
This panel builds off the leadership Novo Nordisk has shown helping patients with the current generation of GLP-1 treatments to explore the opportunities for improving and expanding such treatments via business development and new innovation directions for patients with obesity and other metabolic diseases.
Moderator
Speakers
Director, Strategic Partnering, Cardiometabolism & Retinal Health
Boehringer Ingelheim
Sponsored by:
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())